| 000 | 00957 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250518070841.0 | ||
| 008 | ####s 0 0 eng d | ||
| 022 | _a2572-9241 | ||
| 024 | 7 |
_a10.1097/HS9.0000000000000052 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBorchmann, Peter | |
| 245 | 0 | 0 |
_aThe Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered. _h[electronic resource] |
| 260 |
_bHemaSphere _cJun 2018 |
||
| 300 |
_ae52 p. _bdigital |
||
| 500 | _aPublication Type: Editorial | ||
| 700 | 1 | _aFosså, Alexander | |
| 700 | 1 | _aDługosz-Danecka, Monika | |
| 700 | 1 | _aBöll, Boris | |
| 700 | 1 | _aDietlein, Markus | |
| 700 | 1 | _aKobe, Carsten | |
| 700 | 1 | _aGoergen, Helen | |
| 700 | 1 | _aEngert, Andreas | |
| 773 | 0 |
_tHemaSphere _gvol. 2 _gno. 3 _gp. e52 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/HS9.0000000000000052 _zAvailable from publisher's website |
| 999 |
_c30309664 _d30309664 |
||